Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
The most effective method to Apply Antiquated Ways of thinking in Current Brain science Practices - 2the 6 Shrewd Beds for seniors: A Complete Survey
- 3The most effective method to Guarantee Scholastic Honesty in Web-based Degrees
- 4Scientists captured female sperm whales on video working together during a birth to protect the calf
- 5Trump signs a law returning whole milk to school lunches
- The Best 10 Innovation Developments of the Year
- Lecturer who called Israel a terrorist state to remain Plaid Cymru candidate
- Figure out How to Acquire Rewarding Open Record Rewards
- Virtual Route d: A Survey of \Exploring On the web Stages\ Web Administration
- Extraordinary Snowboarding Objections All over the Planet
- Novo Nordisk cuts Wegovy price as CEO pledges to go 'all in' on weight loss pill
- Exploring the Difficulties of Co-Nurturing: Individual Bits of knowledge
- The most effective method to Succeed in Your Profession with a Web based Advertising Degree
- Miley Cyrus flashes a diamond ring on the red carpet, sparking engagement rumors with Maxx Morando: A timeline of their four-year relationship
